• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 21, 2016

View Archived Issues

Multidrug-resistant bacterial infections

Antibiotic resistance is a natural phenomenon. Acquired resistance rapidly develops because of interspecies gene transmission and selective evolutionary pressure driven by high rates of antibiotic use in hospitals, the community and the agricultural industry. Read More

Drug resistance specter fact of life for antibiotics

In the justified worries about drug resistance, it tends to get somewhat lost that there is, as yet, no completely untreatable superbug. The colistin resistance gene mcr-1 that was detected on plasmids in China and Europe in 2015, and in the US in 2016, has not yet met up with a bacterium that is resistant to all other drugs. Read More

News from ASM

Allergan plc, of Dublin, presented new data highlighting the in vitro activity of Avycaz (ceftazidime and avibactam) against several species of gram-negative pathogens, including certain strains of Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae and Pseudomonas aeruginosa. Read More

In the clinic

Glaxosmithkline plc, of London, and Innoviva Inc., of South San Francisco, reported top-line results from the pivotal phase III FULFIL study of once-daily, triple-combination therapy (fluticasone furoate/umeclidinium/vilanterol, or FF/UMEC/VI) comprising an inhaled corticosteroid, a long-acting muscarinic antagonist and a long-acting beta agonist, in patients with chronic obstructive pulmonary disease. Read More

Other news to note

Adaptimmune Therapeutics plc, of Oxford, U.K., said the EMA Committee for Orphan Medicinal Products has adopted a positive opinion recommending their T-cell therapy targeting NY-ESO for designation as an orphan medicinal product for the treatment of soft tissue sarcoma. Read More

Monitoring, surveillance, cutting inappropriate use can slow brewing crisis

As its genesis so potently illustrates, the rise of antimicrobial resistance (AMR) will not be defused by an antibiotics arms race against the superbug. Read More

Digging for answers (in the ground and IP)

According to the old adage, "Where there's muck, there's brass." And this may prove to be the case for a group of researchers at Northeastern University in Boston, led by Kim Lewis. Their work over the past 18 months has captured media attention following their use of an electronic isolation chip (Ichip) to grow bacteria from soil and then identify and harvest antibiotic compounds contained therein. Read More

Bellus sinks as Kiacta misses in phase III AA amyloidosis study

Long-awaited data from a confirmatory phase III study aimed at convincing regulators of the efficacy of twice-rejected Kiacta (eprodisate) in AA amyloidosis, ended up dealing a crushing blow to Bellus Health Inc., with top-line results Monday showing the five-year, event-driven trial missed the primary endpoint of slowing renal function decline in patients with the orphan disease. Read More

U.K. firms Verona, F2G raise combined $125M ahead of EU vote

DUBLIN – Biotech investors shrugged off short-term fears about any potential fallout from Thursday's looming vote on Britain's continued membership of the EU, pumping more than $125 million into two U.K. firms, Verona Pharma plc and F2G Ltd., which will enable them to move their respective drug candidates into a phase IIb trial in chronic obstructive pulmonary disease (COPD) and a registration study in invasive aspergillosis. Read More

Are we at risk of living in a post-antibiotic world?

Since the mcr-1 gene was found in people and pigs in China last year and then last month the first U.S. case of a patient with an infection resistant to a last-resort antibiotic was reported, tensions are mounting. Read More

Circassia coughs up a phase III hairball in cat allergy study

LONDON – Circassia Pharmaceutical plc's lead immunotherapy program has flopped in a phase III 1,200 -subject trial in cat allergy, sending the shares of the UK's most valuable biotech crashing down by 66 percent. Read More

Orphan endorphins: Add pair to Savara's pipeline with buyout of Serendex

Savara Pharmaceuticals Inc. CEO Rob Neville told BioWorld Today the all-stock buyout of Serendex Pharmaceuticals A/S brings aboard a pair of orphan products, one of them "already enrolling phase II/III" trials in Europe and Japan for pulmonary alveolar proteinosis (PAP). "Being able to pull off an acquisition of a company like Serendex for a private company like us was a big win," he said. Read More

IPRs emerge from high court challenge alive and robust

With Monday's seal of approval from the U.S. Supreme Court, inter partes review (IPR) could be on its way to becoming the drug and device patent challenge of choice. Read More

Financings

Revive Therapeutics Ltd., of Toronto, said it completed its rights offering, which raised $844,693 in gross proceeds. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 23, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BIO2025: John Crowley and Martin Makary

    BIO 2025: Makary lays out FDA’s path, launches pilot review program

    BioWorld
    On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe